Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study.

Vaughn VM, Flanders SA, Snyder A, Conlon A, Rogers MAM, Malani AN, McLaughlin E, Bloemers S, Srinivasan A, Nagel J, Kaatz S, Osterholzer D, Thyagarajan R, Hsaiky L, Chopra V, Gandhi TN.

Ann Intern Med. 2019 Aug 6;171(3):153-163. doi: 10.7326/M18-3640. Epub 2019 Jul 9.

PMID:
31284301
2.

Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation.

Gruca MM, Li Y, Kong X, DeCamillo D, Kline-Rogers E, Ali MA, Kaatz S, Dahu M, Froehlich JB, Barnes GD.

J Thromb Thrombolysis. 2019 Oct;48(3):500-505. doi: 10.1007/s11239-019-01883-0.

PMID:
31111434
3.

Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.

Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S.

Am J Hematol. 2019 Jun;94(6):697-709. doi: 10.1002/ajh.25475. Epub 2019 Apr 16. Review.

PMID:
30916798
4.

Variation in use and outcomes related to midline catheters: results from a multicentre pilot study.

Chopra V, Kaatz S, Swaminathan L, Boldenow T, Snyder A, Burris R, Bernstein SJ, Flanders S.

BMJ Qual Saf. 2019 Sep;28(9):714-720. doi: 10.1136/bmjqs-2018-008554. Epub 2019 Mar 18.

5.

Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events.

Schaefer JK, Li Y, Gu X, Souphis NM, Haymart B, Kline-Rogers E, Almany SL, Kaatz S, Kozlowski JH, Krol GD, Sood SL, Froehlich JB, Barnes GD.

JAMA Intern Med. 2019 Apr 1;179(4):533-541. doi: 10.1001/jamainternmed.2018.7816.

PMID:
30830172
6.

Missed opportunities to prevent upper GI hemorrhage: The experience of the Michigan Anticoagulation Quality Improvement Initiative.

Kurlander JE, Gu X, Scheiman JM, Haymart B, Kline-Rogers E, Saini SD, Kaatz S, Froehlich JB, Richardson CR, Barnes GD.

Vasc Med. 2019 Apr;24(2):153-155. doi: 10.1177/1358863X18815971. Epub 2019 Feb 27. No abstract available.

PMID:
30813868
7.

Periprocedural Bridging Anticoagulation: Measuring the Impact of a Clinical Trial on Care Delivery.

Barnes GD, Li Y, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol G, McNamara M, Froehlich JB, Kaatz S.

Am J Med. 2019 Jan;132(1):109.e1-109.e7. doi: 10.1016/j.amjmed.2018.07.027. Epub 2018 Aug 1.

PMID:
30076828
8.

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.

Berger JS, Seheult R, Laliberté F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.

Res Pract Thromb Haemost. 2017 Nov 15;2(1):58-68. doi: 10.1002/rth2.12050. eCollection 2018 Jan.

9.

Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials.

Hughey AB, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Besley D, Krol GD, Ahsan S, Kaatz S, Froehlich JB, Barnes GD.

J Thromb Thrombolysis. 2018 Oct;46(3):316-324. doi: 10.1007/s11239-018-1698-y.

PMID:
29948756
10.

Extended International Normalized Ratio testing intervals for warfarin-treated patients.

Barnes GD, Kong X, Cole D, Haymart B, Kline-Rogers E, Almany S, Dahu M, Ekola M, Kaatz S, Kozlowski J, Froehlich JB.

J Thromb Haemost. 2018 Jul;16(7):1307-1312. doi: 10.1111/jth.14150. Epub 2018 Jun 6.

11.

CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge.

Laliberté F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S.

Curr Med Res Opin. 2018 Nov;34(11):1967-1974. doi: 10.1080/03007995.2018.1475347. Epub 2018 Jun 12.

PMID:
29749269
12.

Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.

Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, Lentz SR, Kessler CM, Douketis JD, Moll S, Kaatz S, Schulman S, Connors JM, Ginsberg JS, Spadafora L, Bhagirath V, Liaw PC, Weitz JI, Julian JA.

Blood. 2018 May 10;131(19):2151-2160. doi: 10.1182/blood-2017-09-805689. Epub 2018 Feb 28.

13.

Mind the gap: results of a multispecialty survey on coordination of care for peri-procedural anticoagulation.

Kurlander JE, Barnes GD, Anderson MA, Haymart B, Kline-Rogers E, Kaatz S, Saini SD, Krein SL, Richardson CR, Froehlich JB.

J Thromb Thrombolysis. 2018 Apr;45(3):403-409. doi: 10.1007/s11239-018-1625-2.

PMID:
29423559
14.

Risk of Venous Thromboembolism Following Peripherally Inserted Central Catheter Exchange: An Analysis of 23,000 Hospitalized Patients.

Chopra V, Kaatz S, Grant P, Swaminathan L, Boldenow T, Conlon A, Bernstein SJ, Flanders SA.

Am J Med. 2018 Jun;131(6):651-660. doi: 10.1016/j.amjmed.2018.01.017. Epub 2018 Feb 1.

PMID:
29408616
15.

Patterns and Predictors of Short-Term Peripherally Inserted Central Catheter Use: A Multicenter Prospective Cohort Study.

Paje D, Conlon A, Kaatz S, Swaminathan L, Boldenow T, Bernstein SJ, Flanders SA, Chopra V.

J Hosp Med. 2018 Feb;13(2):76-82. doi: 10.12788/jhm.2847.

16.

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants.

Schaefer JK, Sood SL, Haymart B, Gu X, Kong X, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, Froehlich JB, Barnes GD.

Blood Adv. 2017 Dec 7;1(26):2536-2540. doi: 10.1182/bloodadvances.2017012377. eCollection 2017 Dec 12.

17.

Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.

Kaatz S, Coleman CI, Bookhart B, Laliberté F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P.

Curr Med Res Opin. 2018 Feb;34(2):275-284. doi: 10.1080/03007995.2017.1409200. Epub 2017 Dec 22.

PMID:
29164990
18.

Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.

Kaatz S, Mahan CE, Nakhle A, Gunasekaran K, Ali M, Lavender R, Paje DG.

Curr Cardiol Rep. 2017 Oct 24;19(12):124. doi: 10.1007/s11886-017-0930-2. Review.

PMID:
29064044
19.

Reversing factor Xa inhibitors - clinical utility of andexanet alfa.

Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG.

J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017. Review.

20.

Rectus Sheath Hematoma Associated with Apixaban.

Gunasekaran K, Winans ARM, Murthi S, Ahmad MR, Kaatz S.

Clin Pract. 2017 Aug 1;7(3):957. doi: 10.4081/cp.2017.957. eCollection 2017 Jun 7.

21.

The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis.

Chopra V, Kaatz S, Conlon A, Paje D, Grant PJ, Rogers MAM, Bernstein SJ, Saint S, Flanders SA.

J Thromb Haemost. 2017 Oct;15(10):1951-1962. doi: 10.1111/jth.13794. Epub 2017 Sep 13.

22.

Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics.

Barnes GD, Misirliyan S, Kaatz S, Jackson EA, Haymart B, Kline-Rogers E, Kozlowski J, Krol G, Froehlich JB, Sales A.

Implement Sci. 2017 Jul 14;12(1):87. doi: 10.1186/s13012-017-0620-x.

23.

Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.

Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberté F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S.

Clin Ther. 2017 Jul;39(7):1396-1408. doi: 10.1016/j.clinthera.2017.05.357. Epub 2017 Jun 20.

PMID:
28645879
24.

Patterns and Predictors of Peripherally Inserted Central Catheter Occlusion: The 3P-O Study.

Smith SN, Moureau N, Vaughn VM, Boldenow T, Kaatz S, Grant PJ, Bernstein SJ, Flanders SA, Chopra V.

J Vasc Interv Radiol. 2017 May;28(5):749-756.e2. doi: 10.1016/j.jvir.2017.02.005. Epub 2017 Mar 11.

PMID:
28292637
25.

Spontaneous Thyroid Hemorrhage on Chronic Anticoagulation Therapy.

Gunasekaran K, Rudd KM, Murthi S, Kaatz S, Lone N.

Clin Pract. 2017 Feb 6;7(1):932. doi: 10.4081/cp.2017.932. eCollection 2017 Jan 11.

26.

SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience.

Kataruka A, Kong X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, McNamara MW, Froehlich JB, Barnes GD.

Vasc Med. 2017 Jun;22(3):197-203. doi: 10.1177/1358863X16682863. Epub 2017 Feb 1.

27.

Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation: The Michigan Anticoagulation Quality Improvement Initiative Experience.

Barnes GD, Kaatz S, Lopez A, Gu X, Kozlowski J, Krol GD, Froehlich JB.

JAMA Cardiol. 2017 Mar 1;2(3):341-343. doi: 10.1001/jamacardio.2016.5041. No abstract available.

PMID:
28052153
28.

Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant.

Hale ZD, Kong X, Haymart B, Gu X, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, Froehlich JB, Barnes GD.

J Thromb Thrombolysis. 2017 Feb;43(2):283-288. doi: 10.1007/s11239-016-1452-2.

PMID:
27837309
29.

Preclinical and clinical data for factor Xa and "universal" reversal agents.

Milling TJ Jr, Kaatz S.

Am J Emerg Med. 2016 Nov;34(11S):39-45. doi: 10.1016/j.ajem.2016.09.052. Epub 2016 Sep 28. Review.

30.

Bridging Anticoagulation Before Colonoscopy: Results of a Multispecialty Clinician Survey.

Barnes GD, Kurlander J, Haymart B, Kaatz S, Saini S, Froehlich JB.

JAMA Cardiol. 2016 Dec 1;1(9):1076-1077. doi: 10.1001/jamacardio.2016.2409. No abstract available.

PMID:
27627046
31.

Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.

Milling TJ Jr, Kaatz S.

Am J Med. 2016 Nov;129(11S):S80-S88. doi: 10.1016/j.amjmed.2016.06.009. Epub 2016 Aug 27. Review.

32.

D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment.

Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, Lentz SR, Kessler CM, Douketis JD, Moll S, Kaatz S, Schulman S, Connors JM, Ginsberg JS, Spadafora L, Liaw PC, Weitz JI, Julian JA.

Thromb Res. 2016 Oct;146:119-125. doi: 10.1016/j.thromres.2016.06.023. Epub 2016 Jun 23.

PMID:
27354153
33.

Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant.

Minhas AS, Jiang Q, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, Froehlich JB, Barnes GD.

J Thromb Thrombolysis. 2016 Nov;42(4):566-72. doi: 10.1007/s11239-016-1377-9.

PMID:
27217043
34.

Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients.

Greene MT, Spyropoulos AC, Chopra V, Grant PJ, Kaatz S, Bernstein SJ, Flanders SA.

Am J Med. 2016 Sep;129(9):1001.e9-1001.e18. doi: 10.1016/j.amjmed.2016.03.031. Epub 2016 Apr 21.

PMID:
27107925
35.

Variations in Peripherally Inserted Central Catheter Use and Outcomes in Michigan Hospitals.

Chopra V, Smith S, Swaminathan L, Boldenow T, Kaatz S, Bernstein SJ, Flanders SA.

JAMA Intern Med. 2016 Apr;176(4):548-51. doi: 10.1001/jamainternmed.2015.8402. No abstract available.

PMID:
26881938
36.

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism.

Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE.

J Thromb Thrombolysis. 2016 Jan;41(1):187-205. doi: 10.1007/s11239-015-1319-y. Review.

37.

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.

Kaatz S, Ahmad D, Spyropoulos AC, Schulman S; Subcommittee on Control of Anticoagulation.

J Thromb Haemost. 2015 Nov;13(11):2119-26. No abstract available.

PMID:
26764429
38.

Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care.

Guimarães PO, Kaatz S, Lopes RD.

Int J Gen Med. 2015 Sep 7;8:283-91. doi: 10.2147/IJGM.S62760. eCollection 2015. Review.

39.

Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: reply.

Barnes GD, Ageno W, Ansell J, Kaatz S.

J Thromb Haemost. 2015 Nov;13(11):2132-3. doi: 10.1111/jth.13136. Epub 2015 Sep 30. No abstract available.

40.

The changing characteristics of atrial fibrillation patients treated with warfarin.

Putnam A, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, Froehlich JB, Barnes GD.

J Thromb Thrombolysis. 2015 Nov;40(4):488-93. doi: 10.1007/s11239-015-1244-0.

41.

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.

Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL; BRIDGE Investigators.

N Engl J Med. 2015 Aug 27;373(9):823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22.

42.

Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH.

Barnes GD, Ageno W, Ansell J, Kaatz S; Subcommittee on the Control of Anticoagulation of the International Society on Thrombosis and Haemostasis.

J Thromb Haemost. 2015 Jun;13(6):1154-6. No abstract available. Erratum in: J Thromb Haemost. 2015 Aug;13(8):1539.

43.

D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

Kearon C, Spencer FA, O'Keeffe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaatz S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA; D-dimer Optimal Duration Study Investigators.

Ann Intern Med. 2015 Jan 6;162(1):27-34. doi: 10.7326/M14-1275.

PMID:
25560712
44.

Integrating electronic health records in the delivery of optimized anticoagulation therapy.

Nutescu EA, Wittkowsky AK, Witt DM, Kaatz S, Ansell J, Burnett A, Garcia D, Lopes RD, Oertel L, Schnurr T, Streiff M, Wirth D, Crowther M.

Ann Pharmacother. 2015 Jan;49(1):125-6. doi: 10.1177/1060028014548570.

PMID:
25524928
45.

Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome.

Rabinovich A, Cohen JM, Cushman M, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, Tagalakis V, Lazo-Langner A, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Ginsberg JS, Kahn SR.

J Thromb Haemost. 2015 Mar;13(3):398-408. doi: 10.1111/jth.12814. Epub 2015 Feb 10.

46.

Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial.

Kahn SR, Shapiro S, Ducruet T, Wells PS, Rodger MA, Kovacs MJ, Anderson D, Tagalakis V, Morrison DR, Solymoss S, Miron MJ, Yeo E, Smith R, Schulman S, Kassis J, Kearon C, Chagnon I, Wong T, Demers C, Hanmiah R, Kaatz S, Selby R, Rathbun S, Desmarais S, Opatrny L, Ortel TL, Galanaud JP, Ginsberg JS.

Thromb Haemost. 2014 Dec;112(6):1137-41. doi: 10.1160/TH14-05-0430. Epub 2014 Aug 28.

PMID:
25183442
47.

Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism : a cohort study.

Flanders SA, Greene MT, Grant P, Kaatz S, Paje D, Lee B, Barron J, Chopra V, Share D, Bernstein SJ.

JAMA Intern Med. 2014 Oct;174(10):1577-84. doi: 10.1001/jamainternmed.2014.3384.

PMID:
25133488
48.

Evidence-based risk communication: a systematic review.

Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, Kaatz S, Mann DM, Sussman JB, Korenstein D, Schardt C, Nagi A, Sloane R, Feldstein DA.

Ann Intern Med. 2014 Aug 19;161(4):270-80. doi: 10.7326/M14-0295. Review.

PMID:
25133362
49.

Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.

Kaatz S, Fu AC, AbuDagga A, LaMori J, Bookhart BK, Damaraju CV, Tan H, Schein J, Nutescu E.

Thromb Res. 2014 Oct;134(4):807-13. doi: 10.1016/j.thromres.2014.07.027. Epub 2014 Jul 23.

PMID:
25127013
50.

Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782).

Ansell J, Crowther M, Burnett A, Garcia D, Kaatz S, Lopes RD, Nutescu E, Oertel L, Schnurr T, Streiff M, Wirth D, Witt D, Wittkowsky A; Anticoagulation Forum.

Thromb Haemost. 2014 Oct;112(4):841. doi: 10.1160/TH14-04-0325. Epub 2014 Aug 14. No abstract available.

PMID:
25119051

Supplemental Content

Support Center